Primary care program cost-effectively reaches underserved with HCV infection
Last Updated: 2017-11-03
By Marilynn Larkin
NEW YORK (Reuters Health) - The Extension for Community Healthcare Outcomes (Project ECHO) is a cost-effective way to find and treat underserved people with HCV infection using primary care providers, but incremental rollout is needed to mitigate high upfront costs, researchers say.
"To work towards the elimination of HCV - a World Health Organization goal - treatment rates must rise sharply," he observed. "The necessary drugs are still very expensive. They, too, were shown to be cost-effective, but some only barely so."
New drugs, such as the recently FDA-approved glecaprevir and pibrentasvir, marketed as Mavyret, "may bring down costs enough for HCV care to be affordable at a much larger scale," he suggested.
Read more:
http://www.chronicliverdisease.org/reuters/article.cfm?article=20171103Other2087406487
SOURCE: http://bit.ly/2xMgxNV
Gastroenterology 2017.
Last Updated: 2017-11-03
By Marilynn Larkin
NEW YORK (Reuters Health) - The Extension for Community Healthcare Outcomes (Project ECHO) is a cost-effective way to find and treat underserved people with HCV infection using primary care providers, but incremental rollout is needed to mitigate high upfront costs, researchers say.
"To work towards the elimination of HCV - a World Health Organization goal - treatment rates must rise sharply," he observed. "The necessary drugs are still very expensive. They, too, were shown to be cost-effective, but some only barely so."
New drugs, such as the recently FDA-approved glecaprevir and pibrentasvir, marketed as Mavyret, "may bring down costs enough for HCV care to be affordable at a much larger scale," he suggested.
Read more:
http://www.chronicliverdisease.org/reuters/article.cfm?article=20171103Other2087406487
SOURCE: http://bit.ly/2xMgxNV
Gastroenterology 2017.
No comments:
Post a Comment